Skip to main content
SpringerLink
Log in

Que sait-on des modifications phénotypiques et génotypiques entre tumeur primitive et métastase(s) des cancers du sein ?

  • Chapter
Cancer du sein en situation métastatique

  • 223 Accesses

Résumé

Le traitement des patientes au stade métastatique d’un cancer du sein est actuellement fondé sur les caractéristiques phénotypiques de la tumeur initiale. Sachant que les tumeurs primaires de même que les métastases sont très hétérogènes au plan morphologique, phénotypique et génotypique, se pose la question du bien-fondé de cette attitude. En outre, l’hypothèse d’une évolution phénotypique du stade initial à la maladie métastatique liée à l’introduction dès le stade initial de la maladie des nouveaux traitements utilisant des molécules ciblées, ne doit pas être écartée. Ainsi, des modifications phénotypiques pourraient être responsables de l’échec thérapeutique. La question qui mérite d’être posée est la suivante : a-t-on les bonnes cibles du traitement ? Cette question est d’autant plus cruciale que le coût des traitements a décuplé.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Masood S, Bui MM (2000) Assessment of HER-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study. Ann Clin Lab Sci 30: 259–265

    PubMed  CAS  Google Scholar 

  2. Cardoso F, Di Leo A, Larsimont D et al. (2001) Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. Ann Oncol 12: 615–620

    Article  PubMed  CAS  Google Scholar 

  3. Simon R, Nocito A, Hübscher T et al. (2001) Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 93: 1141–1146

    Article  PubMed  CAS  Google Scholar 

  4. Carlsson J, Nordgren H, Sjöström J et al. (2004) HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer 90: 2344–2348

    PubMed  CAS  Google Scholar 

  5. Tanner M, Jarvinen P, Isola J (2001) Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res 61: 5345–5348

    PubMed  CAS  Google Scholar 

  6. Gancberg D, Di Leo A, Cardoso F et al. (2002) Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 13: 1036–1043

    Article  PubMed  CAS  Google Scholar 

  7. Vincent-Salomon A, Jouve M, Genin P et al. (2002) HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer 94: 2169–2173

    Article  PubMed  CAS  Google Scholar 

  8. Zidan J, Dashkovsky I, Stayerman C et al. (2005) Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 93: 552–556

    Article  PubMed  CAS  Google Scholar 

  9. Tapia C, Savic S, Wagner U et al. (2007) HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res 9: R31

    Article  PubMed  Google Scholar 

  10. Guarneri V, Giovannelli S, Ficarra G et al. (2008) Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. Oncologist 13: 838–844

    Article  PubMed  CAS  Google Scholar 

  11. Niehans GA, Singleton TP, Dykoski D et al. (1993) Stability of HER-2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst 85: 1230–1235

    Article  PubMed  CAS  Google Scholar 

  12. Gong Y, Booser DJ, Sneige N et al. (2005). Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 103: 1763–1769

    Article  PubMed  CAS  Google Scholar 

  13. Cottu PH, Asselah J, Lae M et al. (2008) Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer. Ann Oncol 19: 595–597

    Article  PubMed  CAS  Google Scholar 

  14. Iurisci I, Cottu P et al. (2009) Heterogeneous amplification of HER2 is a rare but clinically significant event in invasive ductal carcinoma. SABCS

    Google Scholar 

  15. Solomayer EF, Becker S, Pergola-Becker G et al. (2006) Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients. Breast Cancer Res Treat 98: 179–184

    Article  PubMed  CAS  Google Scholar 

  16. Vincent-Salomon A, Pierga JY, Couturier J et al. (2007) HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management? Br J Cancer 96: 654–659

    Article  PubMed  CAS  Google Scholar 

  17. Meng S, Tripathy D, Shete S et al. (2004) HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 101: 9393–9398

    Article  PubMed  CAS  Google Scholar 

  18. Broom RJ, Tang PA, Summons C et al. (2009) Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer. Anticancer Res 29: 1557–1562

    PubMed  Google Scholar 

  19. Vecchi M, Confalonieri S, Nuciforo P et al. (2008) Breast cancer metastases are molecularly distinct from their primary tumors. Oncogene 27: 2148–2158

    Article  PubMed  CAS  Google Scholar 

  20. Steeg PS, Theodorescu D (2008) Metastasis: a therapeutic target for cancer. Nat Clin Pract Oncol 5: 206–219

    Article  PubMed  CAS  Google Scholar 

  21. Weigelt B, Glas AM, Lodewyk FA et al. (2003) Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci USA 100: 15901–15905

    Article  PubMed  CAS  Google Scholar 

  22. Weigelt B, Hu Z, He X et al. (2005) Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 65: 9155–9158

    Article  PubMed  CAS  Google Scholar 

  23. Hao X, Sun B, Hu L et al. (2004) Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis. Cancer 100: 1110–1122

    Article  PubMed  CAS  Google Scholar 

  24. Feng Y, Sun B, Li X et al. (2007) Differentially expressed genes between primary cancer and paired lymph node metastases predict clinical outcome of node-positive breast cancer patients. Breast Cancer Res Treat 103: 319–329

    Article  PubMed  CAS  Google Scholar 

  25. Suzuki M, Tarin D (2007) Gene expression profiling of human lymph node metastases and matched primary breast carcinomas: clinical implications. Mol Oncol 1: 172–180

    Article  PubMed  Google Scholar 

  26. Wu JM, Fackler MJ, Halushka MK et al. (2008) Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res 14: 1938–1946

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Département de biologie des tumeurs, Institut Curie, 26, rue d’Ulm, 75005, Paris

    B. Sigal-Zafrani & P. de Cremoux

  2. Département d’oncologie médicale, Institut Curie, 26, rue d’Ulm, 75005, Paris

    P. Cottu

Authors
  1. B. Sigal-Zafrani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Cottu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. de Cremoux
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag France

About this chapter

Cite this chapter

Sigal-Zafrani, B., Cottu, P., de Cremoux, P. (2010). Que sait-on des modifications phénotypiques et génotypiques entre tumeur primitive et métastase(s) des cancers du sein ?. In: Cancer du sein en situation métastatique. Springer, Paris. https://doi.org/10.1007/978-2-8178-0076-9_3

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0076-9_3

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0075-2

  • Online ISBN: 978-2-8178-0076-9

Publish with us

Policies and ethics

Search

Navigation